APA (7th ed.) Citation

Döhner, W., Anker, S. D., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., . . . Packer, M. (2022). Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-reduced trial : clinical research : heart failure and cardiomyopathies. European heart journal, 43(36), . https://doi.org/10.1093/eurheartj/ehac320

Chicago Style (17th ed.) Citation

Döhner, Wolfram, et al. "Uric Acid and Sodium-glucose Cotransporter-2 Inhibition with Empagliflozin in Heart Failure with Reduced Ejection Fraction: The EMPEROR-reduced Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal 43, no. 36 (2022). https://doi.org/10.1093/eurheartj/ehac320.

MLA (9th ed.) Citation

Döhner, Wolfram, et al. "Uric Acid and Sodium-glucose Cotransporter-2 Inhibition with Empagliflozin in Heart Failure with Reduced Ejection Fraction: The EMPEROR-reduced Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal, vol. 43, no. 36, 2022, https://doi.org/10.1093/eurheartj/ehac320.